Clinical Trial Update: Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping [Phase 2]

View source ↗

Summary

A Phase 2 open-label study evaluating AOC-1044 for Duchenne muscular dystrophy with mutations amenable to exon 44 skipping is currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• AOC 1044

Snippet

Sponsor: Avidity Biosciences, Inc. | Conditions: DMD, Duchenne Muscular Dystrophy | Phase 2 | Status: ACTIVE_NOT_RECRUITING